Boehringer Ingelheim

Oncology

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

Boehringer, Click DTx for schizophrenia clears pivotal trial

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

PhRMA unveils DTC sales site, as more drugmakers join in

Pharma is embracing DTC selling of medicines in the US, and industry body PhRMA has stepped in to help cut out the middlemen in the supply chain.

R&D

Six things we learned about the obesity market at LSX 2025

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.

ESMO25: Patient-centric oncological futures with Boehringer ...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

Boehringer, Click DTx for schizophrenia clears pivotal trial

Boehringer bags FDA okay for new pulmonary fibrosis drug

PhRMA unveils DTC sales site, as more drugmakers join in

Six things we learned about the obesity market at LSX 2025

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Boehringer Ingelheim

Editor's Picks